Journal article
Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience
SM Garland, SK Kjaer, N Muñoz, SL Block, DR Brown, MJ Dinubile, BR Lindsay, BJ Kuter, G Perez, G Dominiak-Felden, AJ Saah, R Drury, R Das, C Velicer
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2016
DOI: 10.1093/cid/ciw354
Abstract
Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. ..
View full abstractGrants
Funding Acknowledgements
The literature extraction was jointly sponsored and supported by Sanofi Pasteur MSD (Lyon, France) and Merck & Co, Inc (Kenilworth, New Jersey), which manufactures the quadrivalent and nonavalent human papillomavirus (HPV) vaccines under the brand names of Gardasil or Silgard and Gardasil 9, respectively.